Anbefalingen af peroral indgift af 750 mg 3 gange dagligt og 1 000 mg 2 gange dagligt ved svære infektioner (infektioner i luftveje, knogler og led) var imidlertid ikke understøttet af de indsendte data, og CHMP vurderede, at ingen af de foreslåede doseringer kunne inkluderes i markedsføringstilladelsen.
However, the recommendation of the administration of 750 mg tid and 1g bid by oral route in severe infections (respiratory tract infections, bone and joint infections) was not supported by the data submitted and the CHMP considered that none of the proposed posologies could be included in the Marketing Authorisation.